| ID | 1001 |
| Name of the vaccine | BCG |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | Under 1 year |
| Description of the vaccine | BCG vaccine (TICE strain) is for the prevention of tuberculosis. |
| Name of the manufacturer | Organon Teknika Corporation LLC |
| Name of the manufacturing country | Durham |
| Year of manufacture | 1921 |
| Clinical Phase status | Approved |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | Ranges from 0-80%. |
| Vaccine formulation | Lyophilized (freeze-dried) powder |
| Dosage | Adults: 1 mL of sterile water and infants: 2 mL of sterile water for injection. |
| Mechanism of action | Th-1 cell mediated and activate antigen-specific CD4+ T-cells. |
| Route of administration | Percutaneous |
| Indications | Prevention in persons not previously infected with M. tuberculosis and at high risk. |
| Export | Distributed by - Organon USA Inc. Roseland |
| Approval | WHO and US FDA |
| Adjuvant | NA |
| Repurposing | For leprosy also. |
| Side effects of vaccine | Cervical lymphadenopathy, induration, pustule formation, ulceration, regional suppurative lymphadenitis with draining sinuses. |
| Post vaccination | Person should be tuberculin skin tested 2-3 months post vaccination. |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 28955344 |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/78331/download |
| Other name | NA |
| Additional Links | https://www.who.int/immunization/policy/schedule.pdf
|